Know Cancer

forgot password

A Phase II Efficacy and Tolerability Study of RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

Phase 2
18 Years
Not Enrolling
Brain Metastases

Thank you

Trial Information

A Phase II Efficacy and Tolerability Study of RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases

RTA 744 is a novel, anthracycline that has shown the ability to circumvent ATP-binding
cassette transporters (Multidrug Resistance Protein 1, Breast Cancer Resistance Protein,
P-glycoprotein) in vitro. This action enables RTA 744 to penetrate across the blood brain
barrier. In a Phase I safety study, RTA 744 was shown to be generally well tolerated in
patients with recurrent glioblastoma multiforme (GBM). Additionally, anti-tumor activity was
observed. Breast cancer is known to be sensitive to anthracycline therapy. Based on the
preliminary Phase I clinical results and the sensitivity of breast cancer to anthracycline
therapy, this Phase II study will investigate the safety and efficacy of RTA 744 in patients
with breast cancer and metastatic disease to the brain which has progressed following whole
brain irradiation.

Inclusion Criteria:

1. Histologically-confirmed adenocarcinoma of the breast with at least one evaluable
brain lesion ( ≥ 1 cm in one dimension) on contrast-enhanced MRI after WBRT and
documented intracranial failure/progression i. Presence of any new lesion(s); or ii.
≥ 25% increase in bi-dimensional measurement of existing tumor

2. Definitive radiotherapy ≥ 3000 cGy for documented CNS disease completed ≥ 4 weeks
prior to initiation of protocol therapy

3. ≥ 2 weeks since stereotactic radiosurgery or gamma knife therapy

4. ≥ 4 weeks since neurosurgery (open brain or stereotactic brain biopsy). Patients must
have completely recovered from the side effects of surgical procedure.

5. ≥ 2 weeks since major surgery (other than neurosurgical procedure) and complete
recovery from this surgical procedure.

6. Most recent chemotherapeutic treatment regimen completed ≥ 2 weeks prior to study
entry provided toxicities have resolved.

i. Hormone receptor positive patients must have progressed on one prior hormonal AND
at least one prior chemotherapy course in the metastatic setting.

ii. Hormone receptor negative patients must have progressed on at least one prior
chemotherapy course in the metastatic setting.

iii. Her2 positive patients must have progressed on at least one prior
chemotherapeutic and one Her2-targeted combination course in the metastatic setting.

7. Life expectancy ≥ 12 weeks.

8. Patients receiving corticosteroids must have been on a stable dose for 2 weeks prior
to study enrollment.

9. LVEF ≥ 50% on MUGA or ECHO

10. ECOG performance status of 0-2.

11. Laboratory values confirmed within 14 days of initiation of study therapy:
Granulocytes ≥ 1,500/μL; Lymphocytes ≥ 1,000/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥
9 gm/dL; Total Bilirubin < 1.5 times upper limit of normal (ULN); ALT and AST < 1.5
times ULN (< 5 times ULN in patients with liver metastases); Creatinine < 1.5 times

12. Women of childbearing potential must have negative serum pregnancy test, and must
agree to use adequate contraceptive method during administration of study treatment
and for three months after completing treatment.

13. Cognitive ability to provide written informed consent and comply with study
requirements including follow-up procedures.

Exclusion Criteria:

1. Evidence of new or progressive metastatic disease in the brainstem or intramedullary
upper spinal cord. (Metastases in the thalamus are allowed).

2. Evidence of diffuse leptomeningeal disease on brain MRI or by previously documented
CSF cytology. (Discrete dural metastases are permitted.)

3. Evidence of impending herniation on baseline MRI.

4. Evidence of CNS hemorrhage on baseline MRI (within 14 days of study enrollment).

5. Grade 3 or 4 motor, sensory, or cranial neuropathy symptoms; Grade 3 or 4 seizures,
headache or nausea/vomiting.

6. Evidence of bleeding diathesis, coagulopathy or requirement for therapeutic

7. Total lifetime, cumulative anthracycline dose > 350 mg/m2.

8. Impaired cardiac function or other significant cardiac disease or arrhythmia of any
type including: Complete left bundle branch block; Severe aortic stenosis iii.
Obligate use of a cardiac pacemaker; ST depression of > 1mm in ≥ 2 leads and/or T
wave inversions in ≥ 2 contiguous leads; Congenital long QT syndrome; History or
presence of ventricular or atrial arrhythmia; Clinically significant bradycardia; QTc
> 480 msec on EKG; Uncontrolled hypertension, history of labile hypertension or
history of poor compliance with anti-hypertensive regimen; New York Heart Association
(NYHA) Grade II or greater congestive heart failure (CHF); History of myocardial
infarction within the past 6 months within the past 6 months

9. Concurrent or recent (within 4 weeks prior to randomization) medication(s) that may
interfere with study treatment or results, i.e., immunosuppressants other than
corticosteroids, enzyme-inducing anti-epileptics and agents that prolong the QTc.

10. Concurrent or planned hormonal, chemotherapeutic, experimental, or targeted biologic

11. Any of the following concurrent severe or uncontrolled medical condition which could
compromise participation in the study: Uncontrolled diabetes; Active or uncontrolled
infection; Acute or chronic liver disease (i.e. hepatitis, cirrhosis); Patients
having a contraindication to MRI imaging

12. Pregnant

13. Inability to comply with study and/or follow-up procedures.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To evaluate the efficacy of RTA 744 in reducing intracranial tumor on contrast-enhanced MRI of breast cancer patients with progression of brain metastases following whole brain radiotherapy (WBRT).

Outcome Time Frame:

21 Days

Safety Issue:



United States: Food and Drug Administration

Study ID:

RTA 744-C-0703



Start Date:

October 2007

Completion Date:

Related Keywords:

  • Brain Metastases
  • brain metastases
  • breast cancer
  • Breast Neoplasms
  • Neoplasm Metastasis
  • Neoplasms, Second Primary
  • Brain Neoplasms



Virginia Oncology AssociatesNewport News, Virginia  23606
Palm Beach Cancer InstituteWest Palm Beach, Florida  33401
Duke University Medical CenterDurham, North Carolina  27710
Texas Oncology, PADallas, Texas  75246-2006
Forsyth Regional Cancer CenterWinston-Salem, North Carolina  27103
Presbyterian Health CareCharlotte, North Carolina  28204
Moses Cone Regional Cancer CenterGreensboro, North Carolina  27403